Recently, preliminary results of the OLAGLI trial investigating olaparib in 35 patients with recurrent IDH1/2mt high-grade contrast-enhancing gliomas were presented at American Society of Clinical Oncology 2021 (33). Here, IDH1 is linked to glioma.